Moleculin to Present at LD Micro 500 Virtual Investor Conference

Additionally, the Company will hold 1-on-1 virtual investor meetings at the conference.
Investors attending the conference virtually who are interested in meeting with Company management should contact their LD Micro representatives.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses.
Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

HOUSTON, Aug. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will present at the LD Micro 500 Virtual Investor Conference being held virtually on Tuesday, September 1^st, at 4:40pm ET.

Details of the presentation are below:

Event:	LD Micro 500 Virtual Investor Conference
Date:	September 1^st, 2020
Time:	4:40pm ET
Link:	https://www.webcaster4.com/Webcast/Page/2019/36737

Additionally, the Company will hold 1-on-1 virtual investor meetings at the conference. Investors attending the conference virtually who are interested in meeting with Company management should contact their LD Micro representatives.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit http://www.moleculin.com.

Contacts
James Salierno / Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
[email protected]
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/moleculin-to-present-at-ld-micro-500-virtual-investor-conference-301119466.html

SOURCE Moleculin Biotech, Inc.